Secukinumab for Melanoma

(REPLAY Trial)

This trial tests the safety of secukinumab, a medication for individuals with advanced melanoma that has spread to other parts of the body. It targets those who previously received immune checkpoint inhibitors (medicines that help the immune system attack cancer) but had to stop due to side effects like serious skin rashes or liver issues. Participants will receive secukinumab before resuming their previous or new cancer treatment to determine if it helps manage these side effects. For those who experienced these issues during past cancer treatments, this trial might be suitable. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on chronic systemic steroid therapy or other immunosuppressive treatments, you may need to stop them before starting the trial.

Research has shown that Secukinumab is generally safe. Studies on its long-term use indicate that most people tolerate it well for up to five years, with no new safety issues emerging during this period. One study reported a low cancer risk, with only 0.85 cases per 100 patient-treatment years. Additionally, a large safety review found a low risk of serious infections and other severe problems. Overall, extensive research over several years suggests that Secukinumab is safe for patients.¹²³⁴⁵

Secukinumab is unique because it targets interleukin-17A (IL-17A), a protein involved in inflammatory responses, which is different from most melanoma treatments that focus primarily on immune checkpoints like PD-1 or CTLA-4. Researchers are excited about this treatment because it offers a new mechanism of action, potentially enhancing the effectiveness of existing immune checkpoint inhibitors. By combining secukinumab's anti-inflammatory properties with established therapies, there is hope for improved outcomes in melanoma patients who may not fully respond to current options.

Research has shown that secukinumab effectively treats psoriasis by reducing inflammation and improving skin quality. For instance, studies found that after 12 weeks of treatment, nearly 90% of psoriasis patients experienced significant skin improvement. In this trial, participants will receive secukinumab as part of their melanoma treatment regimen. Although direct evidence for using secukinumab in melanoma is limited, it targets a protein called IL-17A, involved in inflammation, which might help manage immune-related side effects from cancer treatments. Importantly, secukinumab carries a low risk of causing new cancers, with a rate of only 0.85 cases per 100 patient-treatment years, suggesting it could be a safe option for patients with a history of cancer.³⁵⁶⁷⁸